TauRx Pharmaceuticals Ltd: LUCIDITY phase 3 topline data presented at CTAD for HMTM - the only oral anti-Tau therapy in late-stage development : vimarsana.com

TauRx Pharmaceuticals Ltd: LUCIDITY phase 3 topline data presented at CTAD for HMTM - the only oral anti-Tau therapy in late-stage development

- Tau aggregation inhibitor, HMTM, is an oral drug with a strong safety profile, having no risk of amyloid related imaging abnormalities - Topline results for the Phase 3 study, LUCIDITY

Related Keywords

China , Canada , United Kingdom , Singapore , San Francisco , California , United States , Scotland , Kostenloser Wertpapierhandel , George Grossberg , Prnewswire Taurx Pharmaceuticals Ltd , St Louis University School Of Medicine , University Of Aberdeen , Clinical Trials , Director Division , Geriatric Psychiatry Department , Behavioural Neuroscience , Taurx , Harmaceuticals , Ucidity , Hase , Opline , Ata , Resented , Tad , Mtm , Nly , Ral , Nti , Herapy , Ate , Tage , Evelopment ,